Correct dosage, usage and precautions of brigatinib

Brigatinib (Brigatinib), as a tyrosine kinase inhibitor (TKI) for ALK-positive metastatic non-small cell lung cancer (NSCLC), its correct use and dosage are crucial to ensure treatment efficacy and patient safety. Below is a detailed dosing guide for brigatinib (brigatinib) .

1. Recommended dosage

The medication process of brigatinib is divided into two phases: the initial phase and the maintenance phase.

1.Initial dose: When the patient takes it for the first time, the recommended dose is 90mg daily for 7 days. The main purpose of this phase is to assess the patient's tolerance to the drug and to minimize the occurrence of early side effects.

2.Maintenance dose: If the patient tolerates the initial dose well, the dose should be increased to 180 mg daily starting from day 8. Maintaining this dose is intended to ensure maximum effectiveness of the drug while maintaining safety for long-term treatment.

2. The correct way to take it

To ensure effective absorption of brigatinib , patients should follow the following instructions:

1.Oral administration:Brigatinib (Brigatinib) is an oral drug and should be swallowed whole and avoid chewing, crushing or splitting. Patients can choose to take it with food or on an empty stomach.

2.Taking it regularly every day: It is recommended to take it at the same time every day to maintain a stable concentration of the drug in the body. If a dose is missed, if it is discovered within 12 hours, the dose should be taken immediately; if it exceeds 12 hours, skip the missed dose and continue taking the next dose at the regular time.

3.Serve with water: Use enough water when taking to ensure that the tablets enter the stomach smoothly.

3. Dose adjustment strategy

The dose of brigatinib may need to be adjusted based on the patient's specific response and side effect profile. Common adjustments include:

1.Side effects management: If the patient experiences severe side effects, such as interstitial lung disease, hypertension or hyperglycemia, the drug may need to be temporarily discontinued or the dose reduced. The general adjustment step is to first reduce from 180mg to 90mg. If it is still intolerable, it can be further reduced to 60mg.

2.Patients with hepatic impairment: Dosage adjustments are generally not required in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should be used with caution and the dose should be adjusted based on clinical response if necessary while being closely monitored.

3.Patients with renal impairment: Patients with mild to moderate renal impairment generally do not need to adjust the dosage. Use with caution in patients with severe renal insufficiency, and dose adjustment if necessary based on clinical response with close monitoring.

4. Precautions for drug interactions

Brigatinib (Brigatinib) is mainly metabolized byCYP3A4, and interactions with other drugs may affect its efficacy and safety. Common interactions include:

1.CYP3A4Inhibitors: PotentCYP3A4inhibitors may increase the plasma concentration of brigatinib (brigatinib) and increase the risk of side effects. If coadministration is necessary, consider reducing the dose of brigatinib and closely monitor for adverse reactions.

2.CYP3A4Inducers: PotentCYP3A4 inducers may reduce the plasma concentration of brigatinib (brigatinib) and weaken its efficacy. If coadministration is necessary, consider increasing the dosage of brigatinib and closely monitor efficacy.

3.Other drugs: When used concurrently with other drugs, possible drug interactions should be closely monitored and the dosage adjusted according to clinical needs.

5. Medication recommendations for special groups

For special groups of people, special attention should be paid when using brigatinib :

1.Elderly patients: Elderly patients should use it with caution as their tolerance to the drug may be lower. Dosage should be adjusted on an individual basis and adverse reactions should be closely monitored.

2.Patients with hepatic and renal impairment: No dose adjustment is required in patients with mild to moderate hepatic or renal impairment. Severe cases should be used with caution and dosage adjusted if necessary, while being closely monitored.

3.Pregnant and lactating women: Pregnant and lactating women are contraindicated brigatinib because it may cause harm to the fetus or infant. If use is necessary, the pros and cons should be weighed and appropriate contraceptive measures taken.

6. Precautions during medication

While using brigatinib , patients should pay attention to the following:

1.Regular monitoring: Routine blood tests, liver function, kidney function, blood sugar and blood pressure should be checked regularly. Eye exams and electrocardiograms should also be performed regularly, especially in patients with relevant symptoms or medical history.

2.Maintain good living habits: avoid smoking and drinking, maintain a healthy diet and a regular schedule. Exercise moderately, but avoid excessive fatigue.

3.Take medication as directed by your doctor: Take brigatinib (brigatinib) strictly in accordance with the doctor's instructions. Do not adjust the dosage or stop the medication on your own. If you have any questions or discomfort, you should consult your doctor promptly.

In summary, brigatinib (Brigatinib) as an important ALK inhibitor, has shown significant effects in the treatment of ALKpositive NSCLC. To ensure its efficacy and safety, patients need to strictly follow the doctor's instructions, closely monitor adverse reactions, and adjust the dosage as needed. At the same time, maintaining good living habits and conducting necessary inspections regularly are also keys to ensuring medication safety.